V posledních letošních „jednohubkách“ hned na úvod příliš nepotěšíme zapřisáhlé pivaře. Naopak zjednodušení by se díky pokrokům ve výzkumu mohl dočkat management péče o nemocné s karcinomem prsu nebo těžkou depresí. A evergreenem zůstává bezpečnost vakcín...

Multiple sclerosis (MS) remains a daunting adversary for most patients. This disease, which affects the brain, spinal cord, and optic nerve, gradually damages the protective myelin sheath of neurons and, in many patients, leads to chronic neurological impairment. Although modern medications can slow the progression, a causal treatment is still lacking. One of the most promising avenues of the past decade is stem cell research —⁠ an approach considered experimental but opening the door to new, yet unexplored therapeutic possibilities.

A recent study by researchers from the German Center for Neurodegenerative Diseases (DZNE) identified a possible link between impaired spatial orientation abilities and an increased risk of dementia associated with Alzheimer’s disease. Virtual reality (VR) played a crucial role in this research.

A recent study published in Biosensors & Bioelectronics describes an innovation that could accelerate the diagnosis of Alzheimer’s disease (AD) and improve treatment outcomes. Researchers at the Korea Research Institute of Standards and Science have developed a tool capable of simultaneously detecting extremely low concentrations of AD biomarkers.

Systematický přehled a metaanalýza studií z let 2011–2024, provedené týmem z Dětského centra Johnse Hopkinse, ukazují, že některé videohry vyvinuté jako digitální intervence mohou být užitečným doplňkem péče u dětí a adolescentů s úzkostnými poruchami, depresí nebo poruchou pozornosti s hyperaktivitou (ADHD).

Gerstmann-Sträussler-Scheinker syndrome (GSS) is a prion disease of the brain. It is an extremely rare but invariably fatal disorder in which a normal protein becomes a destructive pathogen. Although GSS occurs only in a few cases per 100 million people, studying it may help unravel mechanisms underlying neurodegenerative diseases.

The accelerated approval of elamipretide by the U.S. FDA marks a historic milestone in the treatment of mitochondrial diseases. It is the first therapy targeting cardiolipin dysfunction and the first approved drug for patients with Barth syndrome —⁠ an ultra-rare, life-threatening disorder that primarily affects boys.